UNet-3D with Adaptive TverskyCE Loss for Pancreas Medical Image Segmentation

Pancreatic cancer, which has a low survival rate, is the most intractable one among all cancers. Most diagnoses of this cancer heavily depend on abdominal computed tomography (CT) scans. Therefore, pancreas segmentation is crucial but challenging. Because of the obscure position of the pancreas, surrounded by other large organs, and its small area, the pancreas has often been impeded and difficult to detect. With these challenges , the segmentation results based on Deep Learning (DL) models still need to be improved. In this research, we propose a novel adaptive TverskyCE loss for DL model training, which combines Tversky loss with cross-entropy loss using learnable weights. Our method enables the model to adjust the loss contribution automatically and find the best objective function during training. All experiments were conducted on the National Institutes of Health (NIH) Pancreas-CT dataset. We evaluated the adaptive TverskyCE loss on the UNet-3D and Dilated UNet-3D, and our method achieved a Dice Similarity Coefficient (DSC) of 85.59%, with peak performance up to 95.24%, and the score of 85.14%. DSC and the score were improved by 9.47% and 8.98% respectively compared with the baseline UNet-3D with Tversky loss for pancreas segmentation. Keywords: Pancreas segmentation, Tversky loss, Cross-entropy loss, UNet-3D, Dilated UNet-3D

An Inclusive Foundation Model for Generalizable Cytogenetics in Precision Oncology

Chromosome analysis is vital for diagnosing genetic disorders and guiding cancer therapy decisions through the identification of somatic clonal aberrations. However, developing an AI model are hindered by the overwhelming complexity and diversity of chromosomal abnormalities, requiring extensive annotation efforts, while automated methods remain task-specific and lack generalizability due to the scarcity of comprehensive datasets spanning diverse resource conditions. Here, we introduce CHROMA, a foundation model for cytogenomics, designed to overcome these challenges by learning generalizable representations of chromosomal abnormalities. Pre-trained on over 84,000 specimens (~4 million chromosomal images) via self-supervised learning, CHROMA outperforms other methods across all types of abnormalities, even when trained on fewer labelled data and more imbalanced datasets. By facilitating comprehensive mapping of instability and clonal leisons across various aberration types, CHROMA offers a scalable and generalizable solution for reliable and automated clinical analysis, reducing the annotation workload for experts and advancing precision oncology through the early detection of rare genomic abnormalities, enabling broad clinical AI applications and making advanced genomic analysis more accessible.

Automated Quality Evaluation of Cervical Cytopathology Whole Slide Images Based on Content Analysis

The ThinPrep Cytologic Test (TCT) is the most widely used method for cervical cancer screening, and the sample quality directly impacts the accuracy of the diagnosis. Traditional manual evaluation methods rely on the observation of pathologist under microscopes. These methods exhibit high subjectivity, high cost, long duration, and low reliability. With the development of computer-aided diagnosis (CAD), an automated quality assessment system that performs at the level of a professional pathologist is necessary. To address this need, we propose a fully automated quality assessment method for Cervical Cytopathology Whole Slide Images (WSIs) based on The Bethesda System (TBS) diagnostic standards, artificial intelligence algorithms, and the characteristics of clinical data. The method analysis the context of WSIs to quantify quality evaluation metrics which are focused by TBS such as staining quality, cell counts and cell mass proportion through multiple models including object detection, classification and segmentation. Subsequently, the XGBoost model is used to mine the attention paid by pathologists to different quality evaluation metrics when evaluating samples, thereby obtaining a comprehensive WSI sample score calculation model. Experimental results on 100 WSIs demonstrate that the proposed evaluation method has significant advantages in terms of speed and consistency.

Automating tumor-infiltrating lymphocyte assessment in breast cancer histopathology images using QuPath: a transparent and accessible machine learning pipeline

In this study, we built an end-to-end tumor-infiltrating lymphocytes (TILs) assessment pipeline within QuPath, demonstrating the potential of easily accessible tools to perform complex tasks in a fully automatic fashion. First, we trained a pixel classifier to segment tumor, tumor-associated stroma, and other tissue compartments in breast cancer H&E-stained whole-slide images (WSI) to isolate tumor-associated stroma for subsequent analysis. Next, we applied a pre-trained StarDist deep learning model in QuPath for cell detection and used the extracted cell features to train a binary classifier distinguishing TILs from other cells. To evaluate our TILs assessment pipeline, we calculated the TIL density in each WSI and categorized them as low, medium, or high TIL levels. Our pipeline was evaluated against pathologist-assigned TIL scores, achieving a Cohen's kappa of 0.71 on the external test set, corroborating previous research findings. These results confirm that existing software can offer a practical solution for the assessment of TILs in H&E-stained WSIs of breast cancer.

An ensemble deep learning approach to detect tumors on Mohs micrographic surgery slides

Mohs micrographic surgery (MMS) is the gold standard technique for removing high risk nonmelanoma skin cancer however, intraoperative histopathological examination demands significant time, effort, and professionality. The objective of this study is to develop a deep learning model to detect basal cell carcinoma (BCC) and artifacts on Mohs slides. A total of 731 Mohs slides from 51 patients with BCCs were used in this study, with 91 containing tumor and 640 without tumor which was defined as non-tumor. The dataset was employed to train U-Net based models that segment tumor and non-tumor regions on the slides. The segmented patches were classified as tumor, or non-tumor to produce predictions for whole slide images (WSIs). For the segmentation phase, the deep learning model success was measured using a Dice score with 0.70 and 0.67 value, area under the curve (AUC) score with 0.98 and 0.96 for tumor and non-tumor, respectively. For the tumor classification, an AUC of 0.98 for patch-based detection, and AUC of 0.91 for slide-based detection was obtained on the test dataset. We present an AI system that can detect tumors and non-tumors in Mohs slides with high success. Deep learning can aid Mohs surgeons and dermatopathologists in making more accurate decisions.

Identifying regions of interest in whole slide images of renal cell carcinoma

The histopathological images contain a huge amount of information, which can make diagnosis an extremely timeconsuming and tedious task. In this study, we developed a completely automated system to detect regions of interest (ROIs) in whole slide images (WSI) of renal cell carcinoma (RCC), to reduce time analysis and assist pathologists in making more accurate decisions. The proposed approach is based on an efficient texture descriptor named dominant rotated local binary pattern (DRLBP) and color transformation to reveal and exploit the immense texture variability at the microscopic high magnifications level. Thereby, the DRLBPs retain the structural information and utilize the magnitude values in a local neighborhood for more discriminative power. For the classification of the relevant ROIs, feature extraction of WSIs patches was performed on the color channels separately to form the histograms. Next, we used the most frequently occurring patterns as a feature selection step to discard non-informative features. The performances of different classifiers on a set of 1800 kidney cancer patches originating from 12 whole slide images were compared and evaluated. Furthermore, the small size of the image dataset allows to investigate deep learning approach based on transfer learning for image patches classification by using deep features and fine-tuning methods. High recognition accuracy was obtained and the classifiers are efficient, the best precision result was 99.17% achieved with SVM. Moreover, transfer learning models perform well with comparable performance, and the highest precision using ResNet-50 reached 98.50%. The proposed approach results revealed a very efficient image classification and demonstrated efficacy in identifying ROIs. This study presents an automatic system to detect regions of interest relevant to the diagnosis of kidney cancer in whole slide histopathology images.

Contrasting Low and High-Resolution Features for HER2 Scoring using Deep Learning

Breast cancer, the most common malignancy among women, requires precise detection and classification for effective treatment. Immunohistochemistry (IHC) biomarkers like HER2, ER, and PR are critical for identifying breast cancer subtypes. However, traditional IHC classification relies on pathologists' expertise, making it labor-intensive and subject to significant inter-observer variability. To address these challenges, this study introduces the India Pathology Breast Cancer Dataset (IPD-Breast), comprising of 1,272 IHC slides (HER2, ER, and PR) aimed at automating receptor status classification. The primary focus is on developing predictive models for HER2 3-way classification (0, Low, High) to enhance prognosis. Evaluation of multiple deep learning models revealed that an end-to-end ConvNeXt network utilizing low-resolution IHC images achieved an AUC, F1, and accuracy of 91.79%, 83.52%, and 83.56%, respectively, for 3-way classification, outperforming patch-based methods by over 5.35% in F1 score. This study highlights the potential of simple yet effective deep learning techniques to significantly improve accuracy and reproducibility in breast cancer classification, supporting their integration into clinical workflows for better patient outcomes.

TRUSWorthy: Toward Clinically Applicable Deep Learning for Confident Detection of Prostate Cancer in Micro-Ultrasound

While deep learning methods have shown great promise in improving the effectiveness of prostate cancer (PCa) diagnosis by detecting suspicious lesions from trans-rectal ultrasound (TRUS), they must overcome multiple simultaneous challenges. There is high heterogeneity in tissue appearance, significant class imbalance in favor of benign examples, and scarcity in the number and quality of ground truth annotations available to train models. Failure to address even a single one of these problems can result in unacceptable clinical outcomes.We propose TRUSWorthy, a carefully designed, tuned, and integrated system for reliable PCa detection. Our pipeline integrates self-supervised learning, multiple-instance learning aggregation using transformers, random-undersampled boosting and ensembling: these address label scarcity, weak labels, class imbalance, and overconfidence, respectively. We train and rigorously evaluate our method using a large, multi-center dataset of micro-ultrasound data. Our method outperforms previous state-of-the-art deep learning methods in terms of accuracy and uncertainty calibration, with AUROC and balanced accuracy scores of 79.9% and 71.5%, respectively. On the top 20% of predictions with the highest confidence, we can achieve a balanced accuracy of up to 91%. The success of TRUSWorthy demonstrates the potential of integrated deep learning solutions to meet clinical needs in a highly challenging deployment setting, and is a significant step towards creating a trustworthy system for computer-assisted PCa diagnosis.

Exploring Patient Data Requirements in Training Effective AI Models for MRI-based Breast Cancer Classification

The past decade has witnessed a substantial increase in the number of startups and companies offering AI-based solutions for clinical decision support in medical institutions. However, the critical nature of medical decision-making raises several concerns about relying on external software. Key issues include potential variations in image modalities and the medical devices used to obtain these images, potential legal issues, and adversarial attacks. Fortunately, the open-source nature of machine learning research has made foundation models publicly available and straightforward to use for medical applications. This accessibility allows medical institutions to train their own AI-based models, thereby mitigating the aforementioned concerns. Given this context, an important question arises: how much data do medical institutions need to train effective AI models? In this study, we explore this question in relation to breast cancer detection, a particularly contested area due to the prevalence of this disease, which affects approximately 1 in every 8 women. Through large-scale experiments on various patient sizes in the training set, we show that medical institutions do not need a decade's worth of MRI images to train an AI model that performs competitively with the state-of-the-art, provided the model leverages foundation models. Furthermore, we observe that for patient counts greater than 50, the number of patients in the training set has a negligible impact on the performance of models and that simple ensembles further improve the results without additional complexity.

Requirements for Quality Assurance of AI Models for Early Detection of Lung Cancer

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide. Survival largely depends on tumor stage at diagnosis, and early detection with low-dose CT can significantly reduce mortality in high-risk patients. AI can improve the detection, measurement, and characterization of pulmonary nodules while reducing assessment time. However, the training data, functionality, and performance of available AI systems vary considerably, complicating software selection and regulatory evaluation. Manufacturers must specify intended use and provide test statistics, but they can choose their training and test data, limiting standardization and comparability. Under the EU AI Act, consistent quality assurance is required for AI-based nodule detection, measurement, and characterization. This position paper proposes systematic quality assurance grounded in a validated reference dataset, including real screening cases plus phantom data to verify volume and growth rate measurements. Regular updates shall reflect demographic shifts and technological advances, ensuring ongoing relevance. Consequently, ongoing AI quality assurance is vital. Regulatory challenges are also adressed. While the MDR and the EU AI Act set baseline requirements, they do not adequately address self-learning algorithms or their updates. A standardized, transparent quality assessment - based on sensitivity, specificity, and volumetric accuracy - enables an objective evaluation of each AI solution's strengths and weaknesses. Establishing clear testing criteria and systematically using updated reference data lay the groundwork for comparable performance metrics, informing tenders, guidelines, and recommendations.